Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Inclusion Criteria: * Males or females aged 18 or older * Clinical diagnosis of AD by a board certified/eligible dermatologist * Subjects who have body surface area affected to at least 2% total body surface area (BSA) * Subjects with IGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visits * Subjects who can give written informed consent Exclusion Criteria: * Subjects who had topical treatment with corticosteroids within 2 weeks before screening * Subjects who had systemic treatment with corticosteroids or ciclosporin and photopheresis treatment within 2 weeks before screening * Subjects who had ultraviolet irradiation within 2 weeks before screening * Subjects who participated in another drug trial within 4 weeks before screening * Subjects who have an allergy to one of the excipients * Female subjects who have a positive serum pregnancy test at screening, plan a pregnancy during study period, or are breast feeding * Female subjects who don't meet one of the following criteria: Be surgically sterile,Post-menopausal for at least 12 months, or If sexually active, they should use oral contraceptives, double barrier contraception, intrauterine device, or other methods approved by the sponsor * Subjects who have other topical treatment of the AD area * Subjects who take any systemic anti-infective or antibiotic treatment * Subjects who had eczema herpeticum * Subjects who have any clinically significant presence of skin disease or pigmentation other than atopic dermatitis, or wide scar on atopic dermatitis area * Subjects who have poorly-controlled chronic disease * Subjects who have significant medical problems, including but not limited to uncontrolled hypertension and congestive heart failure * Subjects who have clinically significant laboratory abnormalities at screening * Subjects who have a marked prolongation of QT/QTc interval at screening * Subjects who have a history of additional risk factors for TdP * Subjects who use a medication that prolongs the QT/QTc interval * Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures